Anti-Human-Carcinoma-Antigen monoclonal antibody

Drug Profile

Anti-Human-Carcinoma-Antigen monoclonal antibody

Alternative Names: Anti-human carcinoma antigen monoclonal antibody

Latest Information Update: 04 Apr 2003

Price : $50

At a glance

  • Originator Epigen; Medarex
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Prostate cancer

Most Recent Events

  • 04 Apr 2003 No development reported - Preclinical for Prostate cancer in USA (unspecified route)
  • 28 Nov 2000 New profile
  • 28 Nov 2000 Preclinical development for Prostate cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top